The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

After raising $292 million in its Hong Kong IPO, AI discovery and development biotech, Insilico Medicine, signed an R&D collaboration with French pharma Servier SA valued at $888 million to discover ...

The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...

WEST PALM BEACH, Fla (CBS12) — One of the pillars of modern medicine is the life-saving drugs that pharmaceutical companies spend years developing to cure and prevent diseases. But what if they could ...